AGY — Allergy Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- £135.84m
- £132.17m
- £59.59m
2019 June 30th | 2020 June 30th | 2021 June 30th | 2022 June 30th | 2023 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 73.7 | 78.2 | 84.3 | 72.8 | 59.6 |
Cost of Revenue | |||||
Gross Profit | 55.3 | 58 | 62.2 | 49.5 | 33.2 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 69.3 | 69.9 | 80.3 | 85 | 99.2 |
Operating Profit | 4.39 | 8.31 | 4.03 | -12.2 | -39.7 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 4.29 | 8.07 | 3.66 | -12.7 | -41.8 |
Provision for Income Taxes | |||||
Net Income After Taxes | 3.47 | 7.06 | 2.89 | -13.8 | -43.1 |
Net Income Before Extraordinary Items | |||||
Net Income | 3.47 | 7.06 | 2.89 | -13.8 | -43.1 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | 3.47 | 7.06 | 2.89 | -13.8 | -43.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.002 | 0.005 | 0.002 | -0.01 | -0.027 |